Darah practices general corporate and securities law, with an emphasis on complex securities transactions. She represents top investment banks and companies across the healthcare and life sciences, technology, and consumer and retail sectors on equity and debt offerings, including initial public offerings (IPOs), follow-on offerings, private placements, and high-yield, investment-grade and convertible debt offerings.
Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals
August 5, 2025
Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.
Cooley advised the underwriters of Silvaco, a leading provider of technology computer-aided design (TCAD), electronic design animation (EDA) software, and session initiation protocol (SIP) solutions that enable semiconductor design and artificial intelligence through software and innovation, on its $114 million initial public offering.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.
Prelude Therapeutics – $100 Million Follow-on Offering
May 18, 2023
Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.